THE DAY, IN CONTEXTPolaris InsightsAn AI-powered comprehensive news portal

POLARIS INSIGHTS

Astellas Pharma ADR GAAP EPS of v134. 47, revenue of ¥1270. 86B; updates FY2027 outlook

The development centers on astellas Pharma ADR GAAP EPS of v134.47, revenue of ¥1270.86B; updates FY2027 outlook.

Read the full account of the story

More from the Markets desk

More from Markets · Back to Polaris Insights